HAMILTON, ON, Feb. 22, 2024 /PRNewswire/ -- AtomVie Global Radiopharma Inc. (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), is proud to announce strategic collaborations with RLS Radiopharmacies and UPPI LLC. (UPPI), two industry leaders in radiopharmacy and logistics.

2024年2月22日，安大略省汉密尔顿/新闻专线/--领先的放射性药物合同开发和制造组织（CDMO）AtomVie Global Radiopharma Inc.（AtomVie）自豪地宣布与RLS Radiopharmacies和UPPI LLC.（UPPI）的战略合作，UPPI是放射性药物和物流领域的两个行业领导者。

This strategic move is poised to enhance AtomVie's logistics capabilities within the United States, ensuring the widespread distribution of high-quality radiopharmaceuticals by implementing RLS and UPPI as key partners within AtomVie's existing U.S. distribution network. AtomVie specializes in the GMP manufacturing and global distribution of radiopharmaceuticals, RLS the only Joint Commission-accredited radiopharmacy network in the U.S., owns and operates 31 radiopharmacies covering more than 80% of the United States population, and UPPI, organized as a Group Purchasing Organization (GPO), brings extensive capabilities in logistics and distribution..

这一战略举措旨在增强AtomVie在美国的物流能力，通过在AtomVie现有的美国分销网络中实施RLS和UPPI作为关键合作伙伴，确保高质量放射性药物的广泛分销。AtomVie专门从事放射性药物的GMP制造和全球分销，RLS是美国唯一经联合委员会认可的放射性药房网络，拥有并运营着31家放射性药房，覆盖了美国80%以上的人口，而UPPI作为一个集团采购组织（GPO）成立，在物流和分销方面具有广泛的能力。。

Continue Reading

继续阅读

AtomVie Global Radiopharma Collaborates with RLS & UPPI to Strengthen its Existing U.S. Radiotherapeutic Distribution Network

AtomVie Global Radiopharma与RLS&UPPI合作，加强其现有的美国放射治疗分销网络

Radiopharmaceuticals play a pivotal role in precision medicine solutions, providing innovative and promising treatments for various cancer indications. Recognizing the logistics challenges associated with radiopharmaceuticals, given their short half-lives and the critical importance of timely administration; AtomVie, together with RLS and UPPI will bolster its distribution capabilities and allow life-saving treatments to reach more patients..

放射性药物在精准医学解决方案中发挥着关键作用，为各种癌症适应症提供了创新且有前景的治疗方法。认识到与放射性药物相关的后勤挑战，因为它们的半衰期很短，及时管理至关重要；AtomVie与RLS和UPPI一起将增强其分销能力，并使挽救生命的治疗能够惠及更多患者。。

'Our commitment to transforming patient lives through high-quality radiopharmaceuticals is at the core of this partnership with RLS and UPPI,' commented Bruno Paquin, CEO of AtomVie. He added 'These collaborations strengthen our ability to deliver critical radiopharmaceuticals to more locations, ensuring timely access for patients who rely on the products.

AtomVie首席执行官布鲁诺·帕奎因（BrunoPaquin）评论道：“我们致力于通过高质量的放射性药物改变患者的生活，这是与RLS和UPPI合作的核心。”。他补充说，“这些合作加强了我们向更多地点提供关键放射性药物的能力，确保依赖这些产品的患者及时获得这些药物。

These partnerships not only meet the current demand but position us for future growth, as we meaningfully expand our manufacturing capacity and add commercial-scale capabilities.'.

这些合作关系不仅满足了当前的需求，而且为我们未来的增长奠定了基础，因为我们有意义地扩大了制造能力并增加了商业规模的能力。”。

Under the agreements, AtomVie will leverage RLS's and UPPI's extensive radiopharmacy network, as the companies aim to swiftly deliver radiopharmaceuticals to healthcare providers.RLS CEO Stephen Belcher expressed confidence in the partnership's impact on patient care, stating, 'Radiopharmaceuticals begin to decay very rapidly, and it is critical that they reach patients in a safe and timely manner.

根据协议，AtomVie将利用RLS和UPPI广泛的放射性药物网络，因为两家公司的目标是迅速向医疗保健提供商提供放射性药物。RLS首席执行官斯蒂芬·贝尔彻（StephenBelcher）对该合作伙伴关系对患者护理的影响表示信心，他表示，“放射性药物开始迅速衰减，至关重要的是它们必须安全及时地到达患者手中。

That's why this partnership is so important. We are the last mile experts, and by adding our radiopharmacies to its network, AtomVie can ensure its portfolio of life-enhancing therapeutic and diagnostic radiopharmaceuticals reach the right place at the right time, every time.'John Witkowski, President of UPPI highlighted the partnership's impact, promoting greater accessibility and enhanced well-being for individuals, stating 'This partnership is a significant step forward in improving access to life-saving radioisotope-based therapeutics and diagnostics.

这就是为什么这种伙伴关系如此重要。我们是最后一公里的专家，通过将我们的放射药店加入其网络，AtomVie可以确保其增强生命的治疗和诊断放射药物组合在正确的时间，每次都到达正确的地方。”UPPI总裁约翰·维特科夫斯基（JohnWitkowski）强调了该伙伴关系的影响，促进了个人更大的可及性和更高的幸福感，并表示“这一伙伴关系是在改善基于放射性同位素的救生治疗和诊断方法方面迈出的重要一步。

It reflects our joint commitment to delivering precision medicine solutions for patients across the nation.'As leaders in their respective fields, AtomVie, RLS, and UPPI bring unique expertise to this strategic partnership, offering seamless radiopharmaceutical solutions and emphasizing their collective goal to revolutionize patient care by providing consistent access to high-quality radiopharmaceutical options nationwide..

这反映了我们共同致力于为全国患者提供精准医学解决方案。”作为各自领域的领导者，AtomVie、RLS和UPPI为这一战略伙伴关系带来了独特的专业知识，提供了无缝的放射性药物解决方案，并强调了他们的集体目标，即通过在全国范围内提供一致的高质量放射性药物选择来彻底改变患者护理。。

About AtomVie Global Radiopharma Inc.

关于AtomVie Global Radiopharma Inc。

AtomVie Global Radiopharma Inc. (AtomVie) is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace.

AtomVie Global Radiopharma Inc.（AtomVie）是全球领先的CDMO，用于GMP制造以及临床和商业放射性药物的全球分销。AtomVie提供全方位的科学、技术、监管、质量、物流和商业专业知识，并结合专门的基础设施，用于开发从临床研究到商业市场的放射性药物。

AtomVie currently serves international clients conducting studies in over 20 countries worldwide. AtomVie is currently building a state-of-art purpose-built, scalable facility of >70,000 sq ft in Hamilton Ontario that is set to be ready in late 2024. For more information, visit https://www.atomvie.com/.

AtomVie目前为全球20多个国家的国际客户提供研究服务。AtomVie目前正在安大略省汉密尔顿市建造一座规模超过70000平方英尺的先进专用可扩展设施，预计将于2024年底完工。有关更多信息，请访问https://www.atomvie.com/.

About RLS Inc.

关于RLS Inc。

RLS Radiopharmacies (Radioisotope Life Sciences) owns one of the largest radiopharmacy networks in the U.S., with 31 radiopharmacies covering more than 80% of the population. The company also offers an extensive portfolio of diagnostic and therapeutic radiopharmaceutical products. RLS endeavors to supply the highest quality radiopharmaceuticals in the industry by dispensing 100 percent of injectable unit dose products in clean rooms built to ISO 1644-1 specifications.

RLS放射药房（放射性同位素生命科学）拥有美国最大的放射药房网络之一，有31家放射药房覆盖了80%以上的人口。该公司还提供广泛的诊断和治疗放射性药物产品组合。RLS通过在按照ISO 1644-1规范建造的洁净室中分配100%的可注射单位剂量产品，努力提供业界最高质量的放射性药物。

In support of its commitment to quality, RLS provides tailored solutions and exceptional service to more than 1,500 customers. For more information, please visit www.rls.bio..

为了支持其对质量的承诺，RLS为1500多家客户提供量身定制的解决方案和卓越的服务。有关更多信息，请访问www.rls.bio。。

About UPPI LLC

upi LLC

Established in 1998, UPPI has become a leader in traditional nuclear medicine and in the rapidly growing field of theranostics. Representing more than 60 independent and institutional operating sites across the country, UPPI provides its members national strength in buying relationships as well as access to customizable local programs that advance the professionalism of the industry.

UPPI成立于1998年，已成为传统核医学和快速发展的治疗学领域的领导者。UPPI代表全国60多个独立和机构运营网站，为其成员提供购买关系方面的国家实力，并提供可定制的本地计划，以提高行业的专业性。

For more information, visit: www.uppi.orgPhoto - https://mma.prnewswire.com/media/2343869/AtomVie_Global_Radiopharma_Inc__AtomVie_Global_Radiopharma_Colla.jpg .

欲了解更多信息，请访问：www.uppi.org照片-https://mma.prnewswire.com/media/2343869/AtomVie_Global_Radiopharma_Inc__AtomVie_Global_Radiopharma_Colla.jpg。